Balyasny Asset Management
KROS icon

Balyasny Asset Management’s Keros Therapeutics KROS Stock Holding History

Balyasny Asset Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-221,391
Closed -$3.5M – 3057
2024
Q4 		$3.5M Sell
221,391
-104,043
-32% -$5.41M 0.01% 1437
2024
Q3 		$18.9M Buy
325,434
+236,798
+267% +$11.7M 0.03% 660
2024
Q2 		$4.05M Buy
88,636
+63,124
+247% +$3.39M 0.01% 1268
2024
Q1 		$1.69M Buy
25,512
+7,797
+44% +$462K ﹤0.01% 1593
2023
Q4 		$704K Sell
17,715
-27,274
-61% -$855K ﹤0.01% 1822
2023
Q3 		$1.43M Buy
44,989
+34,666
+336% +$1.29M ﹤0.01% 1470
2023
Q2 		$415K Buy
+10,323
New +$453K ﹤0.01% 1912

Other funds holding KROS

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Balyasny Asset Management's KROS Position: Q1 2025 in Review

Balyasny Asset Management sold out of Keros Therapeutics (KROS) in Q1 2025, closing a stake of 221,391 shares — an estimated $3.5M sold.

Balyasny Asset Management first reported a position in KROS in Q2 2023 and held it in 7 quarters. The position peaked at $18.9M in Q3 2024. 156 funds tracked by Wall St. Rank hold KROS as of Q1 2025.

  • Balyasny Asset Management reported no remaining Keros Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 221,391 Keros Therapeutics shares in Q1 2025, an estimated $3.5M.
  • Balyasny Asset Management first reported a position in Keros Therapeutics in Q2 2023 and held it in 7 quarters.
  • Balyasny Asset Management's Keros Therapeutics position peaked at $18.9M in Q3 2024.
  • 156 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2025.

Based on Balyasny Asset Management's 13F filing for Q1 2025, filed 15 May 2025.